Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM1MVQD)

Drug Name
PMID27376512-Compound-MTC-422 Drug Info
Cross-matching ID
TTD Drug ID
DM1MVQD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting DNA [cytosine-5]-methyltransferase 3A (DNMT3A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID27376512-Compound-MTC-424 DMGNRZU N. A. N. A. Patented [1]
PMID27376512-Compound-MTC-427 DMWXEZD N. A. N. A. Patented [1]
PMID27376512-Compound-MTC-423 DM9RSDX N. A. N. A. Patented [1]
PMID27376512-Compound-Figure2aExample1 DMP59OX N. A. N. A. Patented [1]
PMID27376512-Compound-Figure3CN DMP7DL6 N. A. N. A. Patented [1]
PMID27376512-Compound-Figure3CG DMZIKN6 N. A. N. A. Patented [1]
PMID27376512-Compound-Figure3CM DMIS4H0 N. A. N. A. Patented [1]
⏷ Show the Full List of 7 Drug(s)
Drug(s) Targeting DNA [cytosine-5]-methyltransferase 3B (DNMT3B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [2]
PMID27376512-Compound-MTC-424 DMGNRZU N. A. N. A. Patented [1]
PMID27376512-Compound-MTC-427 DMWXEZD N. A. N. A. Patented [1]
PMID27376512-Compound-MTC-423 DM9RSDX N. A. N. A. Patented [1]
(L-)-S-adenosyl-L-homocysteine DMDUN83 Discovery agent N.A. Investigative [3]
NSC-622445 DME35CB Discovery agent N.A. Investigative [2]
NSC-622444 DMM5UT9 Discovery agent N.A. Investigative [2]
NSC-138419 DMH684Q Discovery agent N.A. Investigative [2]
NSC-319745 DMF3G06 Discovery agent N.A. Investigative [2]
NSC-348926 DM3TDEO Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting DNA [cytosine-5]-methyltransferase 1 (DNMT1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CC-486 DMTNQB0 Acute myeloid leukaemia 2A60 Phase 3 [4]
S-110 DMXY34J Acute myeloid leukaemia 2A60 Phase 3 [5]
SGI110 DM1NQDW Acute myeloid leukaemia 2A60 Phase 3 [6]
Guadecitabine DM9Y3EG Myelodysplastic syndrome 2A37 Phase 3 [7]
Palifosfamide DMMIYZ7 Soft tissue sarcoma 2B57 Phase 2 [8]
RX-3117 DME8ARP Bladder cancer 2C94 Phase 2 [9]
Antroquinonol DMRGQVZ Non-small-cell lung cancer 2C25.Y Phase 2 [10]
PMID27376512-Compound-MTC-424 DMGNRZU N. A. N. A. Patented [1]
PMID27376512-Compound-MTC-427 DMWXEZD N. A. N. A. Patented [1]
PMID27376512-Compound-MTC-423 DM9RSDX N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA [cytosine-5]-methyltransferase 1 (DNMT1) TT6S2FE DNMT1_HUMAN Inhibitor [1]
DNA [cytosine-5]-methyltransferase 3A (DNMT3A) TTJUALD DNM3A_HUMAN Inhibitor [1]
DNA [cytosine-5]-methyltransferase 3B (DNMT3B) TT6VZ78 DNM3B_HUMAN Inhibitor [1]

References

1 DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30.
2 Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9.
3 Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6.
4 Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96.
5 S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50.
6 Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84.
9 Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57.
10 Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35.